Table 3 Patients with same mutation in primary melanoma and metastatic dedifferentiated melanoma identified by literature review

From: Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma

Study

# of patients

Histology of metastasis

Molecular findings

Time to metastasis. Range (years)/average (years)

Follow-up status (duration)

Agaimy et al. 2016

4

Patient 1. UPS with myxoid areas.

Patient 2. RMS &

teratocarcinosarcoma-like.

Patient 3. SCS

Patient 4. SCS

BRAF V600E

BRAF V600E

NRAS Q61K

NRAS Q61R

0–2/1

AWD (N/A)

AWD (N/A)

AWD (N/A)

AWD (N/A)

Cipriani et al. 2014

1

UPS

BRAF V600E

42*

N/A

Bekers et al. 2014

2

Patient 1. SFT

Patient 2. SFT

NRAS Q61K

BRAF V600E

7–12/10

N/A

  1. UPS undifferentiated pleomorphic sarcoma, RMS Rhabdomyosarcoma, SCS spindle cell sarcoma, SFT solitary fibrous tumor, AWD alive with disease
  2. * The BRAF analysis was not performed on the primary melanoma but rather on a concurrent metastatic lesion with retained expression of melanocytic markers
Back to article page